Apelin fusion proteins and uses thereof

Patent metadata

Field	Value
Publication number	US-9751921-B2
Application number	US-201615146730-A
Country	US
Kind code	B2
Filing date	May 4, 2016
Priority date	Mar 14, 2013
Publication date	Sep 5, 2017
Grant date	Sep 5, 2017

Abstract

The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or a variant of an Fc domain. Apelin Fc-fusion polypeptides are capable of binding to the apelin receptor (APLNR). Apelin Fc-fusion polypeptides are capable of activating the APLNR and have improved pharmacokinetic properties compared to apelin peptides that are not fused to an Fc or an Fc fragment. Apelin Fc-fusion polypeptides are useful in diseases and conditions related to cardiovascular function, diabetes, cancer, obesity and other apelin-related conditions.

First claim

What is claimed:

1. A polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or variant of an Fc domain, wherein the N-terminus of the apelin peptide is fused to the C-terminus of the Fc domain or fragment or variant thereof, optionally via a peptide linker, and wherein the apelin peptide is a modified apelin 65-77 (apelin-13) peptide having an additional natural amino acid at its C-terminus.

2. The polypeptide of claim 1 , wherein the modified apelin peptide comprises the amino acid sequence of SEQ ID NO: 42.

3. The polypeptide of claim 1 , wherein the modified apelin peptide comprises the amino acid sequence of SEQ ID NO: 43.

4. The polypeptide of claim 1 , wherein the modified apelin peptide comprises the amino acid sequence of SEQ ID NO: 44.

5. The polypeptide of claim 1 , wherein the apelin peptide is fused to the Fc domain, or fragment thereof, via one or more peptide linkers, optionally wherein the one or more peptide linkers comprise one or more Gly-Ser linkers.

6. The polypeptide of claim 1 , wherein the Fc domain is selected from the group consisting of IgG1 CH2 domain and IgG1 CH3 domain; IgG4 CH2 domain and IgG4 CH3 domain; IgG1 CH2 domain and IgG4 CH3 domain; and IgG4 CH2 domain and an IgG1 CH3 domain, optionally wherein the Fc domain further comprises an IgG hinge domain or a fragment or variant thereof.

7. The polypeptide of claim 6 , wherein the Fc domain comprises an IgG hinge domain comprising SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:21, or SEQ ID NO: 22.

8. The polypeptide of claim 1 , wherein the polypeptide (i) is an APLNR agonist that exhibits an EC50 of less than about 10 nM, or less than about 1 nM when measured in an in vitro APLNR activation assay, and/or (ii) has an in vivo half-life of at least about 1 hour, or at least about 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours.

9. A composition comprising the polypeptide of claim 1 and at least one pharmaceutically acceptable carrier or diluent.

10. A nucleic acid molecule encoding the polypeptide of claim 1 .

11. A vector comprising the nucleic acid molecule of claim 10 .

12. A cell comprising the nucleic acid molecule of claim 10 or the vector of claim 11 .

13. The cell of claim 12 , wherein the nucleic acid is stably integrated into the genome of the cell.

14. The cell of claim 13 , wherein the cell is a eukaryotic cell, optionally wherein the cell is selected from the group consisting of CHO, COS, retinal cell, Vero, CV1, 293, MDCK, HaK, BHK, HeLa, HepG2, WI38, MRC 5, Colo25, HB 8065, HL-60, Jurkat, Daudi, A431 (epidermal), CV-1, U937, 3T3, L cell, C127 cell, SP2/0, NS-0, MMT cell, and tumor cell.

15. The cell of claim 13 , wherein the cell is an animal cell, optionally wherein the cell is a mammalian cell.

16. The cell of claim 15 , wherein the cell is a CHO cell.

17. The cell of claim 16 , wherein the cell is a CHO-K1 cell.

18. A polypeptide comprising the amino acid sequence of SEQ ID NO: 39, SEQ ID NO: 40, or SEQ ID NO: 41.

Assignees

• Regeneron Pharma

Inventors

• Stevis Panayiotis
• Murphy Andrew

Classifications

• A61P35/04

  specific for metastasis · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/12

  Antihypertensives · CPC title